Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/34825
Başlık: Cyclosporine-A for severe childhood atopic dermatitis: Clinical experience on efficacy and safety profile
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı.
0000-0001-5555-130X
0000-0001-6407-0962
Sarıcaoğlu, Hayriye
Yazıcı, Serkan
Zorlu, Özge
Bülbül, Başkan Emel
Aydoğan, Kenan
JDD-8680-2023
AAH-2459-2021
ABD-1191-2021
6603722836
25925620000
57203899392
6602518817
9739755800
Anahtar kelimeler: General & internal medicine
Atopic dermatitis
Cyclosporine-A
Treatment
Systemic cyclosporine
Children
Therapy
Yayın Tarihi: 23-Haz-2018
Yayıncı: TÜBİTAK
Atıf: Sarıcaoğlu, H. vd. (2018). ''Cyclosporine-A for severe childhood atopic dermatitis: Clinical experience on efficacy and safety profile''. Turkish Journal of Medical Sciences, 48(5), 933-938.
Özet: Background/aim: Management of atopic dermatitis (AD) in children is still challenging. The aim of this study was to evaluate the efficacy and safety profile of cyclosporine-A (CsA) treatment in children with severe and recalcitrant AD. Materials and methods: Medical records of 43 children followed between January 2010 and December 2015 and treated with systemic CsA were evaluated retrospectively. Treatment efficacy was assessed according to the physician's global assessment (PGA) score. According to the treatment response, patients were grouped as nonresponder, moderate responder, or good responder. Effects of the variables on treatment response were evaluated by analysis of variance (ANOVA). The safety profile of CsA was assessed by clinical and laboratory findings at each visit. Results: The median initial dose of CsA was 3 mg/kg daily, ranging between 2.5 and 5 mg/kg daily. The mean duration of CsA therapy was 4.9 +/- 4.24 months. Seventeen patients (39.5%) achieved good response in a treatment period of 3 to 14 months. After discontinuation of CsA, of the 17 patients, relapse was observed in 4(23.5%). Moderate response was observed in 12(27.9%) patients; however, 14 (32.6) patients did not respond to the treatment. Five patients reported mild side effects. Conclusion: Low-dose CsA seems to be an effective and safe treatment option for severe and recalcitrant AD in children.
URI: https://doi.org/10.3906/sag-1711-7
https://journals.tubitak.gov.tr/medical/vol48/iss5/5/
http://hdl.handle.net/11452/34825
ISSN: 1300-0144
1303-6165
Koleksiyonlarda Görünür:Scopus
TrDizin
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Sarıcaoğlu_vd_2018.pdf123.03 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons